Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03400332 |
TitleA Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers | Phase
Phase 2
|
Date Added 2018-01-17 |
Location
Arkansas, United States
California, United States Colorado, United States Georgia, United States Maryland, United States Massachusetts, United States Michigan, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States Australia Belgium Canada France Germany Italy Poland Spain Sweden Switzerland United Kingdom |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
BMS-986253, Ipilimumab, Nivolumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06322693 |
TitleA Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | Phase
Phase 1
|
Date Added 2024-03-21 |
Location
Arizona, United States
California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Iowa, United States Kansas, United States Kentucky, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Korea, Republic of Spain |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Carboplatin, cisplatin, Docetaxel, Nivolumab, Pemetrexed, TSR-022, TSR-033, TSR-042 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03217747 |
TitleAvelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | Phase
Phase 1, Phase 2
|
Date Added 2017-07-14 |
Location
Texas, United States
|
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Anti-OX40 Antibody PF-04518600, Avelumab, Utomilumab, Bavencio |
Tags
MSS/ MMRp
|
| NCT ID NCT05141721 |
TitleA Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2021-12-02 |
Location
Arizona, United States
Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Maryland, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Wisconsin, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Atezolizumab, Bevacizumab, Fluoropyrimidine, GRT-C901, GRT-R902, Ipilimumab, oxaliplatin |
Tags
MSS/ MMRp
|
| NCT ID NCT04104776 |
TitleA Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas | Phase
Phase 1
|
Date Added 2019-09-26 |
Location
Georgia, United States
Illinois, United States Maryland, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Texas, United States Virginia, United States Washington, United States France Italy Korea, Republic of Poland Spain United Kingdom |
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
CPI-0209, CPI-0209 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05019534 |
TitleTolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2021-08-25 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Camrelizumab, Cetuximab Injection [Erbitux], Vemurafenib Oral Tablet [Zelboraf] |
Tags
MSS/ MMRp
|
| NCT ID NCT03981146 |
TitleA Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer | Phase
Phase 2
|
Date Added 2019-06-10 |
Location
United Kingdom
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Nivolumab, Opdivo |
Tags
MSS/ MMRp
|
| NCT ID NCT04973163 |
TitleA Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation | Phase
Phase 1
|
Date Added 2021-07-22 |
Location
Texas, United States
Belgium Spain United Kingdom |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
BI 1701963, BI 1823911, Midazolam |
Tags
MSS/ MMRp
|
| NCT ID NCT03313778 |
TitleSafety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors | Phase
Phase 1
|
Date Added 2017-10-18 |
Location
Arizona, United States
California, United States District of Columbia, United States Florida, United States Massachusetts, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Australia Japan United Kingdom |
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
mRNA-4157, Pembrolizumab, Keytruda |
Tags
MSS/ MMRp
|
| NCT ID NCT05308446 |
TitleTesting the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation | Phase
Phase 2
|
Date Added 2022-04-04 |
Location
Arizona, United States
California, United States Colorado, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Louisiana, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States New Hampshire, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Puerto Rico |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
cetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, Opdivo |
Tags
MSS/ MMRp
|
